A single subcutaneous 6 mg/kg dose of ADX-038 achieved near-complete alternative pathway inhibition—up to 99.6%—sustained through Day 180 in healthy volunteers, with no measurable impact on the classical pathway. The Phase 1 study (ADX-038 n=31; placebo n=10) reported a generally clean safety profile, with headache and upper respiratory tract infection as the most common adverse events.
ADARx disclosed the interim Phase 1 readout for ADX-038, an siRNA targeting complement factor B, alongside confirmation that multiple Phase 2 studies are underway across complement-mediated indications, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), paroxysmal nocturnal hemoglobinuria (PNH), and geographic atrophy (GA). The biomarker package is the company’s first human validation of deep, durable, pathway-selective suppression and sets up a development path predicated on semi-annual dosing.
Strategically, ADARx is leaning into durability and selectivity to differentiate in a crowded complement market. Oral small molecules, such as factor B inhibitors and C5-directed antibodies, have established clinical and regulatory precedence, but they require chronic dosing and can broadly blunt host defenses. If ADX-038 can consistently silence the alternative pathway while sparing the classical path, it could position itself as a long-acting, subcutaneous option that may mitigate some infection risk and reduce treatment burden. The tension is reversibility: siRNA’s long tail is an asset for adherence and cost of care, but it complicates management of unexpected safety signals and leaves little flexibility to modulate dose intensity once administered.
For sites and CROs, a six-month dosing cadence could materially compress visit schedules, shift operational focus to vaccination status, infection surveillance, and centralized complement assays, and open more room for decentralized follow-up. In renal indications, trial execution will hinge on proteinuria reduction and eGFR slope over six to 12 months, requiring stable background therapy management and careful adjudication to isolate drug effect. PNH programs will be judged against high-response benchmarks set by proximal and terminal complement inhibitors, with breakthrough risk-benefit expectations around hemolysis control, transfusion avoidance, and breakthrough events. In GA, a systemic approach will face a different calculus than intravitreal complement inhibitors, given recent safety debates that have increased regulatory and site scrutiny of inflammation signals. Payers will question whether infrequent dosing translates into lower total cost of care compared with daily or biweekly regimens, especially if infection prophylaxis and monitoring are required.
The immediate watch items are Phase 2 designs and timelines: inclusion criteria that enrich for complement-driven disease biology, durability of suppression in patients versus healthy volunteers, and early efficacy signals in IgAN and C3G that can support accelerated pathways. Safety will be the gating factor—demonstrating preserved classical pathway function is encouraging. However, programs will still need robust vaccination strategies and clear protocols for managing serious infections under long-acting suppression. Operationally, sponsors should anticipate tighter pharmacovigilance and rescue plans given limited reversibility. If ADX-038 converts biomarker depth into clinically meaningful outcomes without compromising safety, it could force a re-think of dosing logistics in complement therapy; if not, incumbents with flexible dosing and established benefit will remain challenging to dislodge.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
